FindMyKOL
Clinical trialNCT00765557CompletedPhase Early 1Interventional

Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome

NCT00765557 is a phase early 1 interventional trial sponsored by University of Texas Southwestern Medical Center. As of 18 Nov 2026, it is completed. It studies MiraLAX and Placebo in Constipation. The registry lists an enrollment of 138 participants. The registry lists a start date of 10 Dec 2007 and a primary completion date of 17 Jun 2014.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00765557
FieldValue
Registry IDNCT00765557
StatusCompleted
PhasePhase Early 1
Study typeInterventional trial
Lead sponsorUniversity of Texas Southwestern Medical Center
Enrollment138
ConditionsConstipation
DrugsMiraLAX and Placebo
Start10 Dec 2007
Primary completion17 Jun 2014
Study completion22 Jul 2014
Last update posted15 Jan 2021

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

HYPOTHESIS: Is MiraLAX an effective treatment of pediatric urinary urge syndrome? OBJECTIVE: Polyethylene glycol (PEG) is common first-line therapy for urinary symptoms despite minimal evidence-based support. We performed a randomized, double-blind, placebo-controlled study of PEG for initial treatment of urinary urge symptoms. SUMMARY: Only patients of investigators and sub-investigators will be recruited for this study. Children with urinary incontinence, urinary frequency, diurnal incontinence, Urinary Tract Infection (UTI) and/or reflux validated by bladder/bowel symptom questionnaire to have Urge Syndrome (US) are eligible for this study. A standardized questionnaire of bowel/bladder activity will be administered and a KUB obtained as standard of care at entry to the study. A standard 1-day voiding diary will be completed at home before beginning therapy. To exclude patients potentially still in the process of toilet training, only subjects 4 years of age and older will be studied. Other exclusion criteria will include known neurological disorders, a diagnosis of attention deficit disorder, bladder symptoms less than 6 months in duration at presentation, other bladder dysfunctions besides US, a history of anorectal malformation and pregnancy. Based upon prior experience that patients with encopresis were not likely to achieve improved stooling with only a few weeks of laxative therapy, they will also be excluded. Those accepted into the study will be randomized to receive either laxative or placebo once daily for one month. Preparation of the laxative and placebo and patient randomization will be performed by the Children's Medical Center Investigational Drug Pharmacist. Premixed study medications will be available at the Urology clinic ready to be dispensed to the patient by the study coordinator after being screened and randomized. Dosage includes children age 4-6 years (8.5 gms) and children 7-10 years (17gms). The medication will be divided into daily doses by the Investigational Pharmacist. Written and verbal instructions, both in English and Spanish, will be provided to the parents/guardian of the subjects. The Investigational Drug Pharmacist will be blinded to all patient data, and physicians and nurses evaluating patients will be blinded to randomization of these patients to laxative versus placebo arms.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

MiraLAXPlacebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00765557

Each answer restates registry values shown on this page.

What is NCT00765557?

NCT00765557 is a phase early 1 interventional trial sponsored by University of Texas Southwestern Medical Center. It studies MiraLAX and Placebo in Constipation.

Who leads NCT00765557?

The registry names Warren T Snodgrass, MD (principal investigator, PARC Urology) as the overall official.

Which drugs does NCT00765557 study?

The registered drug and biological interventions are MiraLAX and Placebo.

When did NCT00765557 end?

The registry lists a primary completion date of 17 Jun 2014 and a study completion date of 22 Jul 2014. The sponsor last updated the record on 15 Jan 2021.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.